Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 20, 2014
Pharmacy Choice - News - U.S. Pharmaceutical Industry - October 20, 2014

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/20/14 - "Hepatic Protection Agent Containing Eggshell Membrane and Pharmaceutical Composition, Food Additive and Food Using the Same" in Patent Application...
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors KATO, Hisanori; JIA, HuiJuan; HASEBE, Yukio, filed on April 25, 2013, was made available online on October 9, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to ALMAD
10/20/14 - "Pharmaceutical Compositions Comprising a Local Anaesthetic Such as Bupivacaine for Local Administration to the Mouth Or Throat" in Patent...
"Pharmaceutical Compositions Comprising a Local Anaesthetic Such as Bupivacaine for Local Administration to the Mouth Or Throat" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Andersen, Ove; Mogensen, Stine; Treldal, Charlotte; Mogensen, Torben; Pulis, Syl
10/20/14 - Abbott Laboratories' Trademark Application for "ACT 1" Filed
By a News Reporter-Staff News Editor at Clinical Trials Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "ACT 1" by Mary L. Winburn, representing Abbott Laboratories. The owner/registrar information for this application is: Mary L. Winburn, Abbott Laboratories, D3
10/20/14 - Abbott Laboratories' Trademark Application for "INFO HQ" Filed
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "INFO HQ" by Michele H. Bowman, representing Abbott Laboratories. The owner/registrar information for this application is: Michele H. Bowman, Abbott Laboratori
10/20/14 - Abbott Laboratories' Trademark Application for "NUTRIVIGOR" Filed
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "NUTRIVIGOR" by Cheryl A. Withycombe, representing Abbott Laboratories. This application was made available to the public on October 02, 2014. The owner/regist
10/20/14 - Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna
Today, Analysts Review released its research reports regarding AbbVie Inc., Gilead Sciences Inc., Pfizer Inc., Eli Lilly and Company and Aetna Inc.. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7291-100free. AbbVie Inc. Research Report s On October 16, 2014, Bloomberg reported that AbbVie I
10/20/14 - Advanced Cell Technology Appoints LeRoux Jooste as SVP of Business Development & Chief Commercial Officer
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced the appointment of LeRoux Jooste to the newly created position of Senior Vice President of Business Development and Chief Commercial Officer. LeRoux joins ACT from Antares Pharma Inc., where he served as Senior Vice President and General Manager, Pharmac
10/20/14 - Advaxis Appoints David J. Mauro, M.D., Ph.D., as Chief Medical Officer
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed David J. Mauro, M.D., Ph.D., as Executive Vice President, Chief Medical Officer of Advaxis. Dr. Mauro brings to Advaxis more than 14 years of experience in oncology drug development, clinical research, and medical affairs
10/20/14 - Advaxis, Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities (Oct. 8, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Advaxis, Inc. was posted on October 8, 2014. The SEC file number is 0001493152-14-003251.. A U.S. Securities and Exchange Commission filing is a form
10/20/14 - Advaxis, Inc. Files SEC Form 8-K, Current Report (Oct. 8, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Advaxis, Inc. was posted on October 8, 2014. The SEC file number is 0001493152-14-003249.. A U.S. Securities and Exchange Commission filing is a form
10/20/14 - Affymax Inc. Files SEC Form S-8 POS, Securities To Be Offered To Employees in Employee Benefit Plans, Post-effective Amendments (Oct. 7, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Affymax Inc. was posted on October 7, 2014. The SEC file number is 0001158223-14-000028.. A U.S. Securities and Exchange Commission filing is a forma
10/20/14 - Agile Therapeutics Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities (Oct. 2, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agile Therapeutics Inc. was posted on October 2, 2014. The SEC file number is 0001104659-14-069736.. A U.S. Securities and Exchange Commission filing
10/20/14 - Agile Therapeutics Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Oct. 2, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agile Therapeutics Inc. was posted on October 2, 2014. The SEC file number is 0001104659-14-069738.. A U.S. Securities and Exchange Commission filing
10/20/14 - Agile Therapeutics Inc. Files SEC Form 8-K, Current Report (Oct. 2, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agile Therapeutics Inc. was posted on October 2, 2014. The SEC file number is 0001104659-14-069653.. A U.S. Securities and Exchange Commission filing
10/20/14 - Alexion Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Oct. 7, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alexion Pharmaceuticals Inc. was posted on October 7, 2014. The SEC file number is 0000899866-14-000216.. A U.S. Securities and Exchange Commission f
10/20/14 - Alexion Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Oct. 7, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alexion Pharmaceuticals Inc. was posted on October 7, 2014. The SEC file number is 0000899866-14-000211.. A U.S. Securities and Exchange Commission f
10/20/14 - Allergan Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Oct. 3, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Allergan Inc. was posted on October 3, 2014. The SEC file number is 0001127602-14-029438.. A U.S. Securities and Exchange Commission filing is a form
10/20/14 - Allergan Inc. Files SEC Form DFAN14A, Additional Definitive Proxy Soliciting Materials Filed By Non-management And Rule 14(A)(12) Material (Oct. 3,...
Allergan Inc. Files SEC Form DFAN14A, Additional Definitive Proxy Soliciting Materials Filed By Non-management And Rule 14 Material. By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Allergan Inc. wa
10/20/14 - Allergan Inc. Files SEC Form PREC14A, Preliminary Proxy Statements, Contested Solicitations (Oct. 7, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Allergan Inc. was posted on October 6, 2014. The SEC file number is 0001193125-14-364996.. A U.S. Securities and Exchange Commission filing is a form
10/20/14 - Allergan Inc. Files SEC Form SC 14D9, Solicitation, Recommendation Statements [Amend] (Oct. 8, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Allergan Inc. was posted on October 7, 2014. The SEC file number is 0001193125-14-365920.. A U.S. Securities and Exchange Commission filing is a form
10/20/14 - Alnylam Pharmaceuticals, Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities (Oct. 3, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alnylam Pharmaceuticals, Inc. was posted on October 3, 2014. The SEC file number is 0001325812-14-000049.. A U.S. Securities and Exchange Commission
10/20/14 - Alnylam Pharmaceuticals, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Oct. 3, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alnylam Pharmaceuticals, Inc. was posted on October 3, 2014. The SEC file number is 0001209191-14-061843.. A U.S. Securities and Exchange Commission
10/20/14 - Amgen's BiTE Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia
By a News Reporter-Staff News Editor at Biotech Business Week Amgen announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for the investigational bispecific T cell engager antibody construct, blinatumomab. As part of the acceptance, the FDA granted blinatumomab priority review with a Prescr
10/20/14 - Amicus Therapeutics Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Oct. 2, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amicus Therapeutics Inc. was posted on October 2, 2014. The SEC file number is 0001209191-14-061296.. A U.S. Securities and Exchange Commission filin
10/20/14 - Amicus Therapeutics Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals (Oct. 8, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amicus Therapeutics Inc. was posted on October 7, 2014. The SEC file number is 0001306923-14-000008.. A U.S. Securities and Exchange Commission filin
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415